Tetraphase (NASDAQ: TTPH) is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVATM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company.
Status: Public
ReGenX Biosciences
ReGenX Biosciences (NASDAQ: RGNX) is a leading AAV (adeno-associated virus) gene therapy company with a broad platform technology based on its proprietary NAV vector technology platform.
Proteostasis Therapeutics
Proteostasis Therapeutics is a drug discovery company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Proteostasis Therapeutics went public in 2016 (NASDAQ: PTI). The company merged with Yumanity Therapeutics in 2020 and is no longer traded with the ticker symbol PTI.
Mersana Therapeutics
Mersana Therapeutics (NASDAQ: MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Laurus Labs
Laurus Labs (NSE: LAURUSLABS) is a leading manufacturer of Active Pharmaceutical Ingredients (API) for anti-retroviral (HIV-AIDS), oncology, nutraceutical and several other products, with a customer base that spans top-tier generic pharmaceutical companies in India and abroad.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) developed linaclotide, a first-in-class therapy that received FDA approval for both irritable bowel syndrome and chronic constipation.
Innovent Biologics
Innovent Biologics (1801.HK) has built a robust pipeline of innovative and commercially promising monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases.
Hua Medicine
Hua Medicine (2552.KHK) is a leading clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders.
Hile BioPharma
Hile (603718.SS) is a leading animal vaccine manufacturer that specializes in sales, marketing and commercialization of animal vaccine products in China.
Dimension Therapeutics
Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics went public in 2015 (NASDAQ: DMTX). The company has since been acquired by Ultragenyx Pharmaceuticals and is no longer a publicly traded company.